Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Teva Pharmaceutical Industries Ltd

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Present at the Jefferies London Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Statement on European Commission Decision; Company to Appeal
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Present at the Bank of America 2024 Global Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Tickers TEVA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.